There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders

Medical Science Monitor

Volumn 19, Issue , 2013, Pages 888-891

  Akman Karakaş, Ayşe ^a   Yalcin, Arzu Didem ^b   Koç, Saliha ^a   Gumuslu, Saadet ^a   Yiǧiter Şenol, Yeşim ^a   Özkesici, Birgül ^a   Genc, Gizem Esra ^a   Ergun, Erkan ^a   Ongut, Gozde ^a   Yilmaz, Ertan ^a   Uzun, Soner ^a   Alpsoy, Erkan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Autoimmune; Inflammatory; Pemphigus; Psoriasis; Skin; Soluble CD200 (sCD200)

Indexed keywords

CD200 ANTIGEN; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE SKIN DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MALE; PATHOGENESIS; PEMPHIGUS VULGARIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; SCORING SYSTEM;

ANALYSIS OF VARIANCE; ANTIGENS, CD; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PEMPHIGUS; PSORIASIS;

EID: 84887346552     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889624     Document Type: Article

References (20)

1. Barclay AN, Wright GJ, Brooke G, Brown MH: CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol, 2002; 23: 285-90
2. Chen Z, Marsden PA, Gorczynski RM: Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-g and tumor necrosis factor-a. Mol Immunol, 2009; 46: 1951-63
3. Simelyte E, Criado G, Essex D et al: CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum, 2008; 58: 1038-43
4. Chakera A, Bennett SC, Morteau O et al: The phenotype of circulating follicular-helper T cells in patients with rheumatoid arthritis defines CD200 as a potential therapeutic target. Clin Dev Immunol, 2012; 2012: 948218
5. Holmannová D, Kolácková M, Kondélková K et al: CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; Part I: CD200/CD200R structure, activation, and function. Acta Medica (Hradec Kralove), 2012; 55: 12-17
6. Rosenblum MD, Olasz EB, Yancey KB et al: Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance? J Invest Dermatol, 2004; 123: 880-87
7. Copland DA, Calder CJ, Raveney BJ et al: Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol, 2007; 171: 580-88
8. Yalcin AD, Genc GE, Celik B, Gumuslu S: Anti-IgE monoclonal antibody (omalizumab) is effective in treating Bullous Pemphigoid and effects on soluble CD200. Clin Lab, 2014; 60(3-4)
9. Yalcin AD, Karakas AA, Soykam G et al: A Case of Toxic Epidermal Necrolysis with Diverse Etiologies: Successful Treatment with Intravenous Immunoglobulin and Pulse Prednisolone and Effects on TRAIL and sCD200 Levels. Clin Lab, 2013; 59: 681-85
10. Schmidt E, Zillikens D: Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev, 2010; 10: 84-89
11. Rosenbach M, Murrell DF, Bystryn JC et al: Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol, 2009; 129: 2404-10
12. Gorczynski RM: CD200: CD200R-Mediated Regulation of Immunity. ISRN Immunology 2012, doi: 10.5402/2012/682168
13. Yalcin AD, Ucar S, Gumuslu S, Strauss L: Effects of Omalizumab on Eosinophil Cationic Peptid, 25-Hydroxyvitamin-D, IL-1b, and sCD200 in a cases of Samter's syndrome: 36 Months follow-up. Immunopharmacol Immunotoxicol, 2013; 35: 524-27
14. Yalcin AD, Cilli A, Bisgin A et al: Omalizumab is effective in treating severe asthma in patients with severe cadiovascular complications and effects on sCD200, d-dimer, CXCL8 and IL-1b levels. Expert Opin Biol Ther, 2013; 13(9): 1335-41
15. Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T: Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol, 2013; 169(2): 266-82
16. Bacaksiz A, Erdogan E, Sonmez O et al: Ambulatory blood pressure monitoring can unmask hypertension in patients with psoriasis vulgaris. Med Sci Monit, 2013; 19: 501-9
17. Grando SA, Bystryn JC, Chernyavsky AI et al: Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Exp Dermatol, 2009; 18(9): 764-70
18. Dubois Declercq S, Pouliot R: Promising new treatments for psoriasis. Scientific World Journal, 2013; 2013: 980419
19. Sadik CD, Zillikens D: Skin-specific drug delivery: a rapid solution to skin diseases? J Invest Dermatol, 2013; 133(9): 2135-37
20. Kouno M, Lin C, Schechter NM et al: Targeted Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand to Keratinocytes with a Pemphigus mAb. J Invest Dermatol, 2013; 133(9): 2212-20